Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700944 | 1.00 | CYP17A1 (0.46) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL4030831 | 0.93 | CYP17A1 (0.46) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL7105236 | 0.88 | CYP17A1 (0.46) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL7105239 | 0.88 | CYP17A1 (0.46) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL7103624 | 0.88 | CYP17A1 (0.46) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL5700914 | 0.83 | CYP17A1 (0.47) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL5700917 | 0.83 | CYP17A1 (0.47) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL23818376 | 0.82 | CYP17A1 (0.49) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL16277092 | 0.82 | CYP17A1 (0.49) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 | |
| SCHEMBL31471413 | 0.80 | CYP17A1 (0.45) | CYP17A1PPARGPPARAMAPKAPK2PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177181-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | AVENTIS PHARMA LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| EP-1027328-B1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-6562851-B2 | Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
| US-6479519-B1 | INHIBITORS OF CELL ADHESION; TREATMENT OF ASTHMA OR INFLAMMATORY BOWEL DISEASE | AVENTIS PHARMA LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| US-20020156111-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-10-24 | — | — | US | disclosed |
| EP-1177181-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | Aventis Pharma Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068213-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156111-A1 | Substituted bicyclic compounds | VCAM1, ITGA1, ITGA5 | CYP17A1 836/4885PPARG 1273/4885PPARA 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.